0QT6.LSE Genfit S.A.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.
Is 0QT6.LSE undervalued?
Graham numberThe Graham number of Genfit S.A. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Genfit S.A. fundamental analysis
No fundamental analysis for Genfit S.A. yet.
Genfit S.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Genfit S.A.
Genfit S.A., together with its subsidiaries, engages in the research and development of medicines and diagnostic solutions in France and internationally. The company offers elafibranor for the treatment of primary biliary cholangitis; and NIS, a non-invasive diagnostic technology for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops elafibranor, which is in Phase 3 clinical trial for the treatment of primary sclerosing cholangitis; GNS561, w…
Full company profileGenfit S.A. financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Genfit S.A. annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 6.78M | 6.86M | 7.49M | 41.0M | 7.76M | - | - | - |
| Gross Profit | 4.80M | 4.63M | 5.64M | 38.8M | 5.68M | - | - | - |
| Operating Income | -34.2M | -56.7M | -69.5M | -57.8M | -82.9M | - | - | - |
| Net Income | -33.7M | -55.7M | -79.5M | -65.1M | -101M | - | - | - |
| Balance Sheet | ||||||||
| Total Assets | 166M | 293M | 229M | 310M | 199M | - | - | - |
| Total Liabilities | 23.4M | 192M | 209M | 226M | 215M | - | - | - |
| Shareholders' Equity | 143M | 101M | 20.9M | 84.1M | -16.2M | - | - | - |
| Cash & Short-term Investments | 152M | 274M | 207M | 277M | 171M | - | - | - |
| Total Debt | 5.00M | 158M | 163M | 176M | 178M | - | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | -27.2M | -49.9M | -56.1M | -47.7M | -96.4M | 99.9M | - | - |
| Capital Expenditure | 2.04M | 2.80M | 2.94M | 2.03M | 900K | 537K | 0.00 | - |
| Ratios | ||||||||
| ROE | -23.6% | -54.9% | -379.8% | -77.5% | - | - | - | - |
| ROA | -20.3% | -19.0% | -34.7% | -21.0% | -51.0% | - | - | - |
| Net Profit Margin | -496.3% | -812.8% | -1,061.1% | -159.0% | -1,304.7% | - | - | - |
| Debt to Equity | 0.04x | 1.56x | 7.79x | 2.09x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Genfit S.A. dividends
Genfit S.A. has not paid dividends in the last 9 fiscal years.
Last stock split: 1739:1687 on Oct 12, 2016.
Who owns Genfit S.A.
- Insiders 13.22%
- Institutions 14.45%
- Public & others 72.34%
- Free float 41.1M
Genfit S.A. company profile
- Company name
- Genfit S.A.
- Ticker
- 0QT6.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 180
- Fiscal year end
- December
- Address
- Parc Eurasanté, Loos, France, 59120
- Phone
- 33 3 20 16 40 00
- Website
- genfit.com
About Genfit S.A.
Genfit S.A., together with its subsidiaries, engages in the research and development of medicines and diagnostic solutions in France and internationally. The company offers elafibranor for the treatment of primary biliary cholangitis; and NIS, a non-invasive diagnostic technology for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops elafibranor, which is in Phase 3 clinical trial for the treatment of primary sclerosing cholangitis; GNS561, which is in Phase 1b clinical trial for the treatment of cholangiocarcinoma; and G1090N/NTZ, which is in Phase 1 clinical trial for the treatment of acute-on-chronic liver failure continuum. In addition, the company is involved in the development of drugs in preclinical stage, including SRT-015, CLM-022, and EViv for the treatment of acute-on-chronic liver failure continuum; VS-02-HE for the treatment of hepatic encephalopathy; and VS-01-HAC (UCD/OA) for the treatment of hyperammonemic crises, urea cycle disorder, and organic acidemias. It has strategic partnerships with Ipsen for the development and commercialization of elafibranor; and Labcorp for the development and commercialization of NASHnext, a blood-based molecular diagnostic test, as well as TS-01, a diagnostic tool for blood ammonia levels. The company was incorporated in 1999 and is headquartered in Loos, France.
Genfit S.A. management
10- Mr. Jean-Francois MouneyCo-Founder & Chairman of the Board · born 1955
- Mr. M. Pascal PrigentChief Executive Officer · born 1968
- Mr. John BrozekExecutive VP of Data & Information Technology and Director · born 1977
- Prof. Bart StaelsCo-Founder & Chairman of the Scientific Advisory Board · born 1963
- Mr. Thomas BaetzChief Financial Officer · born 1974
- Mr. Pascal CaiseyDeputy CEO & COO · born 1968
- Ms. Sakina Sayah-JeanneChief Scientific Officer · born 1972
- Mr. Jean-Christophe MarcouxChief Corporate Affairs Officer, Head of Investor Relations & Head of ESG · born 1977
- Mr. Laurent LannooCorporate Secretary & Director of Legal Affairs · born 1970
- Ms. Stefanie Magner J.D.Chief Compliance Officer & Executive VP of International Legal Affairs · born 1981